In cases with MAF < 1% by OncoBEAM, plasma mutational analysis was also compared to tissue-based methods on paired primary tumor specimens in order to independently examine the clinical sensitivity of Idylla and OncoBEAM plasma KRAS mutation detection. Here, KRAS is linked to neoplasm.